Novo Nordisk Target Price 2025 – Novo nordisk stock prediction for april 2025. In may, the positive dynamics for novo nordisk a/s shares will prevail with possible monthly volatility of 11.220% volatility is expected. How much will novo nordisk shares cost tomorrow? Positive dynamics for novo nordisk shares will prevail with possible volatility of 0.993%.
Maximum price 104.51, minimum 76.99. The forecast for beginning 90.65 dollars. Averaged novo nordisk stock price for the month 91.92. Novo nordisk stock price stood at $90.85.
Novo Nordisk Target Price 2025
Novo Nordisk Target Price 2025
The highest price target for nvo is $160.00, while the lowest price target for nvo is $105.00. What is novo nordisk a/s's forecast for 2025? Novo nordisk stock price forecast for march 2025.
Explore novo nordisk’s stock price predictions for 2025, 2026 and 2030, driven by the success of ozempic and its expanding role in diabetes and obesity treatments. Novo nordisk will rise to $125 within the year of 2028, $150 in 2029 and $200 in 2032. The average price target represents a forecasted upside of 66.60% from the current price of $87.19.
The average target predicts an increase of 56.28% from the current stock price of 90.65. Novo nordisk stock price predictions for 2025, 2026, 2027 using artificial intelligence. The weighted average target price per novo nordisk share in may 2025 is:
Novo Nordisk Stock (NYSENVO) Can Wegovy Justify Its Valuation? Nasdaq
Novo Nordisk missed its diversity targets last year. Its CEO paid the price Fortune Europe
Novo Nordisk Stock Slides Before Q4 Earnings Analysts Still See 68 Upside Novo Nordisk (NYSENVO) Benzinga
Novo Nordisk A/S (NVO) Price Prediction and Forecast 20252030 24/7 Wall St.
Novo Nordisk Can Danish Giant Justify Valuation Greater Than Home Country's GDP?
Novo shares hits 9month low as 2025 guidance underwhelms Reuters
Novo Nordisk's Future Boom or Bubble?
Novo Nordisk CEO on earnings Very bullish on 2025 despite demand concerns
Assessing Novo Nordisk Insights From 10 Financial Analysts Markets Insider
Novo Nordisk Unexpected Surge Analyzed
